Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9923033 | 0.82 | OPRM1 (0.47) | OPRM1OPRD1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL9899906 | 0.80 | NISCH (0.46) | OPRM1OPRD1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL6017360 | 0.76 | OPRM1 (0.49) | OPRM1OPRD1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL3853218 | 0.74 | ALOX5 (0.53) | OPRM1OPRD1KMT2ASMN1; SMN2POLB | |
| SCHEMBL8321455 | 0.73 | KMT2A (0.44) | KMT2ASMN1; SMN2POLBKDM4EHTT | |
| SCHEMBL9725754 | 0.72 | ALOX5 (0.40) | KMT2APOLBKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL9725757 | 0.72 | ALOX5 (0.40) | KMT2APOLBKDM4EHSD17B10ALDH1A1 | |
| SCHEMBL12938059 | 0.71 | ALDH1A1 (0.45) | OPRM1OPRD1KMT2AKDM4EHSD17B10 | |
| SCHEMBL13995841 | 0.71 | ALDH1A1 (0.45) | OPRM1OPRD1KMT2AKDM4EHSD17B10 | |
| SCHEMBL13995839 | 0.71 | ALDH1A1 (0.45) | OPRM1OPRD1KMT2AKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149691-A1 | Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors | JAK1, JAK2, JAK3 | OPRM1 4194/4885OPRD1 4044/4885KMT2A 774/4885 |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | OPRM1 4238/4885OPRD1 4266/4885KMT2A 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.